Evotec, Indivumed to Collaborate On Precision Medicine For Colorectal Cancer

The collaboration leverages Indivumed’s true multi-omics cancer database “IndivuType” and Evotec’s drug discovery platforms to identify new therapeutics for colorectal cancer

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Indivumed GmbHannounced today that they have entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of colorectal cancer (“CRC”). The collaboration, which runs for an initial term of two years, will combine Evotec’s proprietary bioinformatics analysis platform “PanHunter” as well as its small molecule and antibody discovery platforms with the CRC cohort of Indivumed’s true multi-omics cancer database “IndivuType”. The goal of this precision medicine collaboration is to deliver highly effective and durable treatments with clear strategies for CRC patient stratification.

https://www.marketscreener.com/EVOTEC-AG-436047/news/Evotec-And-Indivumed-Announce-Strategic-Drug-Discovery-Collaboration-On-Precision-Medicine-For-Col-28387687/